CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 ...
Phase 3
Toronto, Ontario, Canada and 17 other locations
In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a li...
Phase 2, Phase 3
Toronto, British Columbia, Canada and 1 other location
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...
Phase 3
Oshawa, Ontario, Canada and 68 other locations
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing ...
Phase 4
Stouffville, Ontario, Canada and 89 other locations
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Phase 3
North York, Ontario, Canada and 81 other locations
control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes...
Phase 2
Toronto, Ontario, Canada and 26 other locations
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic...
Phase 3
Toronto, Ontario, Canada and 78 other locations
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medic...
Phase 3
Toronto, Ontario, Canada and 179 other locations
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, co...
Phase 2
Toronto, Ontario, Canada and 48 other locations
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increas...
Phase 3
Toronto, Ontario, Canada and 648 other locations
Clinical trials
Research sites
Resources
Legal